Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematological Diseases, Non-MalignantHematologic NeoplasmsSolid TumorsProtocol groupAcute LeukemiasAggressive LymphomasCellular TherapyHemolytic DiseasesHodgkin LymphomaIndolent LymphomasNeuro-OncologyRadiotherapyT-Cell and NK-Cell NeoplasmsTransplantationDiseaseAcute Lymphoblastic LeukaemiaCAR T-Cell TherapyChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaHodgkin LymphomaMalignant MeningitisMantle Cell LymphomaNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Marginal Zone LymphomaNHL, B-Cell Type, Mediastinal (Thymic) Large B-Cell LymphomaNHL, T-Cell Type, Anaplastic Large CellNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK-positiveNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK negativeNHL, T-Cell Type, AngioimmunoblasticNHL, T-Cell Type, Enteropathy TypeNHL, T-Cell Type, HepatosplenicNHL, T-Cell Type, Other Specified Leukemias, Aggressive NK-Cell LeukemiaNHL, T-Cell Type, Peripheral, UnspecifiedPrimary Lymphoma of the CNSSubgroupCD20+Lymphomatous Meningitismolecular high grade (MHG)non-GCBRichter transformation, DLBCLunfitICD10C79.3C81.-C82.-C82.7C82.9C83.-C83.0C83.1C83.3C83.7C84.4C84.6C84.7C85.2C85.9C86.1C86.2C86.5C88.0-C91.0-C91.1-C94.7-MeSHLymphoma, Large-Cell, AnaplasticLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellLymphoma, T-CellLymphoma, T-Cell, PeripheralMeningeal CarcinomatosisSequenceCOALITIONECHELON-3EPCO(0.16/0.8/48), DLBCL, C1 (PID2486) -|- C2-3 (PID2487) -|- C4-9 (PID2488) -|- C10+ (PID2489)EPCORE NHL-2: EPCO(0.16/0.8/3/48)/GEMC1000/OXAL100, DLBCL, C1 (PID2927) -|- C2-3 (PID2928) -|- C4 (PID2929) -|- C5-9 (PID2930) -|- C10+ (PID2489)IXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)LOTIS-2: -|- LONTES150, DLBCL, C1-2 (PID2229) -|- LONTES75, DLBCL, C3+ (PID2230)MOLTO: OBIN(100/900/1000)/ATEZ1200/VNTC20, CLL (Richter Syndrome), C1 (PID2778) -|- C2 (PID2779) -|- C3-8 (PID2780) -|- C9-18 (PID2781) -|- C19-35 (PID2782)MOR208: TAFA12/LENA25, DLBCL, C1 (PID1848) -|- C2-3 (PID1849) -|- C4-12 (PID1850) -|- C13+ (PID1851)MOSU(1/2/60), B-NHL, C1 (PID2105) -|- C2 (PID2106) -|- C3+ (PID2107)OBIN1000/GLOF(2.5/10), DLBCL, C1 (PID2393) -|- GLOF30, C2-12 (PID2394)ODRO(0.2/0.5/2/10), DLBCL, C1 (PID2886) -|- ODRO160, C2 (PID2893) -|- C3-4 (PID2894) -|- ODRO320, maint. 2 (PID2895) -|- maint. 4 (PID2896)OXAL25/FLUD30/CYTA1000/RITU375, CLL-RT, C1 (PID828) -|- C2+ (PID829)POLARIX: Pola-R-CHP (POLVED1,8/RITU375/CYCL750/DOXO50/PRED100), DLBCL, C1-6 (PID1920) -|- RITU375, C7-8 (PID1921)POLVED1,8/MOSU(1/2/60), DLBCL, C1 (PID2812) -|- C2 (PID2813) -|- C3-6 (PID2814) -|- C7-17 (PID2815)R-ACVBP (RITU375/DOXO75/CYCL1200/VIND2/BLEO10/PRED60) ind., DLBCL A (PID340) -|- cons., B (PID341) -|- cons., C (PID342) -|- cons., D (PID343)R-CHOP 14 (RITU375/CYCL750/DOXO50/VNCR2/PRED100), DLBCL, C1-6 (PID112) -|- RITU375, C7-8 (PID1448)R-CHOP 14 smart (RITU375/CYCL750/DOXO50/VNCR2/PRED100), DLBCL, C1 (PID926) -|- C2 (PID929) -|- C3 (PID930) -|- C4 (PID929) -|- C5 (PID930) -|- C6 (PID929) -|- C7+ (PID75)R-CHOP 21 (RITU375/CYCL750/DOXO50/VNCR2/PRED100)/MTRX12, Testicular Lymphoma, C1 (PID901) -|- C2 (PID902) -|- C3-6 (PID903)R-DHAOx (RITU375/OXAL130/CYTA2000/DEXA40), DLBCL, C1 (PID3115) -|- C2 (PID3118) -|- C3-6 (PID3119)R-ICE (RITU375/ETOP100/CRBP5/IFOS5), DLBCL, C1 (PID348) -|- C2+3 (PID349)REMoDL-B: R-CHOP (RITU375/CYCL750/DOXO50/VNCR2/PRED100), DLBCL, C1 (PID2681) -|- R-CHOP (RITU375/CYCL750/DOXO50/VNCR2/PRED100)/BORT1,6, C2-6 (PID2682)RITU375/PGLDX30/CYCL750/VNCR2/PRED40, DLBCL, C1 (PID2502) -|- C2-6 (PID2503)RITU375/POLVED1.8/BEND90, DLBCL, C1 (PID1422) -|- C2-6 (PID1423)STARGLO: OBIN1000/GEMC1000/OXAL100/GLOF(2,5/10), DLBCL, C1 (PID2808) -|- C2-8 (PID2809) -|- C9-12 (PID2810)STUDY - levelSTUDY OPTIMAL, Arm F-ASTUDY OPTIMAL, Arm F-BSTUDY OPTIMAL, Arm LF-ASTUDY OPTIMAL, Arm LF-BSTUDY OPTIMAL, Arm LF-CSTUDY OPTIMAL, Arm LF-DViPOR (OBIN1000/PRED100/IBRU560/LENA15/VNTC(50/200/600/800)), DLCBL, C1 (PID2666) -|- C2-6 (PID2677)VNCR1/PRED60, DLBCL (PID1778) -|- C1 (PID2535) -|- C2-6 (PID2536)ChemotherapyChemo-substanceAtezolizumabBendamustineBleomycinBortezomibBrentuximab vedotinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDecitabineDexamethasoneDoxorubicinDoxorubicin liposomalDoxorubicin pegylated liposomalEpcoritamabEtoposideFludarabineGemcitabineGlofitamabHuman albumin 20%IbrutinibIfosfamideLenalidomideLoncastuximab TesirinMelphalanMethotrexateMethylprednisoloneMitoxantroneMosunetuzumabNaCl 0.9%NivolumabObinutuzumabOdronextamabOxaliplatinPixantronPolatuzumab vedotinPrednisoloneProcarbazineRituximabSelinexorTafasitamabVenetoclaxVincristineVincristine liposomalVindesineChemo-substanceAtezolizumabBendamustineBleomycinBortezomibBrentuximab vedotinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDecitabineDexamethasoneDoxorubicinDoxorubicin liposomalDoxorubicin pegylated liposomalEpcoritamabEtoposideFludarabineGemcitabineGlofitamabHuman albumin 20%IbrutinibIfosfamideLenalidomideLoncastuximab TesirinMelphalanMethotrexateMethylprednisoloneMitoxantroneMosunetuzumabNaCl 0.9%NivolumabObinutuzumabOdronextamabOxaliplatinPixantronPolatuzumab vedotinPrednisoloneProcarbazineRituximabSelinexorTafasitamabVenetoclaxVincristineVincristine liposomalVindesineChemo-substanceAtezolizumabBendamustineBleomycinBortezomibBrentuximab vedotinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDecitabineDexamethasoneDoxorubicinDoxorubicin liposomalDoxorubicin pegylated liposomalEpcoritamabEtoposideFludarabineGemcitabineGlofitamabHuman albumin 20%IbrutinibIfosfamideLenalidomideLoncastuximab TesirinMelphalanMethotrexateMethylprednisoloneMitoxantroneMosunetuzumabNaCl 0.9%NivolumabObinutuzumabOdronextamabOxaliplatinPixantronPolatuzumab vedotinPrednisoloneProcarbazineRituximabSelinexorTafasitamabVenetoclaxVincristineVincristine liposomalVindesineChemo-substanceAtezolizumabBendamustineBleomycinBortezomibBrentuximab vedotinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDecitabineDexamethasoneDoxorubicinDoxorubicin liposomalDoxorubicin pegylated liposomalEpcoritamabEtoposideFludarabineGemcitabineGlofitamabHuman albumin 20%IbrutinibIfosfamideLenalidomideLoncastuximab TesirinMelphalanMethotrexateMethylprednisoloneMitoxantroneMosunetuzumabNaCl 0.9%NivolumabObinutuzumabOdronextamabOxaliplatinPixantronPolatuzumab vedotinPrednisoloneProcarbazineRituximabSelinexorTafasitamabVenetoclaxVincristineVincristine liposomalVindesineNo. Substances123456 RadiotherapySupportive therapySupportive substanceAcetylsalicylic acidAciclovirAllopurinolAmphotericin BAprepitantBalanced Crystalloid SolutionCimetidineCiprofloxacinCotrimoxazoleDalteparinDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronLipegfilgrastimMagnesiumMagnesium sulfateMesnaNaCl 0.9%PantoprazoleParacetamolPegfilgrastimPotassium chloridePrednisolonePyridoxineSodium BicarbonateSupportive substanceAcetylsalicylic acidAciclovirAllopurinolAmphotericin BAprepitantBalanced Crystalloid SolutionCimetidineCiprofloxacinCotrimoxazoleDalteparinDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronLipegfilgrastimMagnesiumMagnesium sulfateMesnaNaCl 0.9%PantoprazoleParacetamolPegfilgrastimPotassium chloridePrednisolonePyridoxineSodium BicarbonateSupportive substanceAcetylsalicylic acidAciclovirAllopurinolAmphotericin BAprepitantBalanced Crystalloid SolutionCimetidineCiprofloxacinCotrimoxazoleDalteparinDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronLipegfilgrastimMagnesiumMagnesium sulfateMesnaNaCl 0.9%PantoprazoleParacetamolPegfilgrastimPotassium chloridePrednisolonePyridoxineSodium BicarbonateSupportive substanceAcetylsalicylic acidAciclovirAllopurinolAmphotericin BAprepitantBalanced Crystalloid SolutionCimetidineCiprofloxacinCotrimoxazoleDalteparinDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronLipegfilgrastimMagnesiumMagnesium sulfateMesnaNaCl 0.9%PantoprazoleParacetamolPegfilgrastimPotassium chloridePrednisolonePyridoxineSodium BicarbonateNo. Substances123456789101112Protocol classificationTherapy classificationalternativecurrent standardolder age and/or reduced general conditionstudy analogStudy protocol, currentIntensityDose intensifiedhigh doseStandard doseTherapy indicationFirst lineRefractory diseaseRelapse therapySecond lineseveral possibleThird line Therapy phaseConsolidationInductionMaintenancePre-phaseReinductionSalvageTherapy intentioncurativecurative or palliativedisease controlpalliativeRisksAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlAstheniaBleedingCardiotoxicityConstipationCOVID-19 infectionCytokine Release SyndromeDiarrheaDyspneaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaGastrointestinal ToxicityHeadacheHemorrhageHepatotoxicityHerpes ZosterHypercalcemiaHyperglycemiaHyperkalemiaHypertensionHypoalbuminemiaHypocalcemiaHypokalemiaHypomagnesemiaHyponatremiaHypophosphatemiaHypotensionIncrease AminotransferasesInfectionsInfusion ReactionLeukopeniaLymphopeniaMucositisMyalgiasNeuropathyNeurotoxicityNeutropeniaOral MucositisPainPhotosensitivityPneumoniaPruritusPyrexiaRashRenal FailureSepsisThrombocytopenia below 50 000/µlThromboembolic EventTumor Lysis SyndromeUpper Respiratory Tract InfectionVenous ThrombosisVomiting only studiesPublicationAuthorAbramson JAbramson JSAydin SBannerji RBartlett NLBias PBrody JDBudde LEChao NJCoiffier 2002Crump MDavies ADavies AJDickinson MJDuell JEl Gnaoui TFields PAFurqan FGisselbrecht CGopal AHeld GHerbrecht RKalakonda NKirschey SLiu E Luminari SMartin AMelani CMinson AMoccia AAOberic L Pettengell RPeyrade FPfreundschuhPfreundschuh MRodriguez MARubenstein JRécherSchmitz NSchuster SJSehn LSekiguchi YStorti STedeschi ATessoulin BThieblemont CTilly HTsimberidou AVelasquez WSVitolo UWeidmann EWitzig TEZaja FZhang MCDiseaseAggr. B-NHL, Rezidiv oder therapierefraktäraggr. B-NHL incl. DLBCL, nach Rezidiv oder bei fehlendem CR unter Erstlinie mit CHOP, ECOG 0-1Aggr. B-NHL über 80 Jahre oder unter 80 mit KI gegen R-CHOP, ErstlinieAggr. oder de novo transf. B-NHL, Rezidiv - Drittlinie und höher, ECOG 0-2aggressive, CD 20+ B-NHL, 18-60 Jahre, Erstlinie, ECOG 0-3Aggressive B-NHL, Patienten zwischen 65 und 85 Jahren, ECOG 0-2aggressive CD20+ B-NHL, 61-80 Jahre, ECOG 0-1aggressive CD20+ B-NHL, 61-80 Jahre, ECOG 0-4aggressive CD20+ B-NHL, 61-80 Jahre, Hochrisiko-Patienten, ECOG 0-1Aggressives B-NHL, 61-80 Jahre, Erstlinie, ECOG 0-2B-NHL, refraktär oder rezidivierend, ohne Eignung zur HochdosistherapieB-NHL, rezidiviert oder therapierefraktär, CD19- positiv, Lymphodepletion vor CAR T-Zell TherapieB-NHL, Zweitlinie nach CD20 Antikörper, ECOG 0-1B-NHL mit aggressiver Histologie (DLBCL, Mantelzell-Lymphom), CD20+, rezidiviert / therapierefraktärB-Non-Hodgkin-Lymphom/Hodgkin LymphomCoiffier 2002: DLBCL, 60-80 Jahre, ECOG 0-2, Erstlinie , Cunningham 2013: DLBCL, ab 18 Jahren, ECOG 0-3, Erstlinie.diffus großzelliges B-Non-Hodgkin-Lymphom, 2-5 Vortherapien, nicht geeignet für autologe SCT, ECOG 0-2diffus großzelliges Non-Hodgkin-Lymphom, HochrisikoDLBCL, 60-75 J., ErstlinieDLBCL, Ann-Arbor II-IV, CR oder PR nach 6-8 Zyklen R-CHOP, 60-80 J., ECOG 0-2DLBCL, Ann Arbor Stadium I-IV, über 80 J., ECOG 0-2DLBCL, Erstlinie, bis 59 JahreDLBCL, Erstlinie, IPI 2-5, ECOG 0-2DLBCL, Erstlinie, Kontraindikation für AnthrazyklineDLBCL, IPI 2 oder höher, ECOG 0-2DLBCL, kardiale Komorbiditäten mit Kontraindikation für die Anthrazyklingabe, ErstlinieDLBCL, Kontraindikation für AnthrazyklineDLBCL, rezidiviert oder therapierefraktär, CD20+, ECOG 0-2DLBCL, rezidiviert oder therapierefraktär, mind. 2 VortherapienDLBCL, Rezidiv nach mind. 2 Vortherapien, ASCT ungeeignet oder bereits unterzogen, Lymphodepletion vor CAR-T-Zell TherapieDLBCL, Rezidiv nach mind. 2 Vortherapien, ASCT ungeeignet oder bereits unterzogen, Lymphodepletion vor CAR T-Zell TherapieDLBCL, Rezidiv oder refraktär, mit mindestens einer anthrazyklinhaltigen VortherapieDLBCL, Stadium I (bulky disease) oder Stadium II-IV, ECOG 0-2, ErstlinieDLBCL, Stadium II - IV, CD20+, Erstlinie, ECOG 0-2DLBCL, über 80 Jahre, ECOG 0-2, ErstlinieDLBCL Stadium I-IV, älter als 60 Jahre, Erstlinie, ECOG 0-2Fludarabin-refraktäre CLL oder Transormation zum Richter Syndrom, ECOG 0-2Hochrisiko-LBCL (mind. eines der folgenden Kriterien: IPI mind. 3, NCCN-IPI mind 4 oder das Vorliegen eines Double-Hit-Lymphoms), 18-65 J., ECOG 0-3Hodenlymphom, Stadium I-II, ECOG 0-1Lymphom, rezidiviert oder therapierefraktärLymphom, Rezidiv oder refraktär, mit mindestens einer anthrazyklinhaltigen VortherapieNon-Hodgkin-Lymphom / Hodgkin LymphomR/R DLBCL, mindestens 1 Vortherapie, ECOG 0-2, nicht geeignet für eine ASCT, periphere Neuropathie bis Grad 1R/R DLBCL, mindestens 2 Vortherapien, nicht für intensive Therapie geeignet, ECOG 0-2Refraktäres oder rezidivierendes Non-Hodgkin-Lymphomrezidivierendes (erstlinie mit Anthrazyklin) oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2, ECOG 0-2rezidivierendes oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2rezidivierendes oder refraktäres Non-Hodgkin-Lymphom, ECOG 0-2rezidivierte aggressive B-NHL, 18-65 Jahre, ECOG 0-2Rezidivierte oder refraktäre, aggressive Lymphome, 2. Linie vor ASCT, ECOG 0-3Rezidiviertes DLBCL, 1-3 Vortherapien, ungeeignet für eine ASCTrezidiviertes oder refraktäres B-NHL, mindestens zwei vorherige systemische BehandlungenRezidiviertes oder refraktäres diffus großzelliges Lymphom, ECOG 0-2Rezidiviertes oder refraktäres DLBCL, nicht transplantationsfähigRezidiviertes und therapierefraktäres DLBCL, 1-3 Vortherapien, ECOG 0-1Rezidiviertes und therapierefraktäres DLBCL, follikuläres Lymphom °IIIB, mind. 2 Vortherapien, ECOG 0-2Rezidiviertes und therapierefraktäres DLBCL, nicht zur Transplantation geeignet, ECOG 0-1Rezidiviertes und therapierefraktäres DLBCL, nicht zur Transplantation geeignet ECOG 0-1Richter Transformation (DLBCL) bei chronischer lymphatischer Leukämieunbehandeltes diffus großzelliges B-Non-Hodgkin Lymphom bei älteren, gebrechlichen Patienten (>70 Jahre)Wiederkehrendes oder refraktäres ZNS Lymphom primär oder NHL, CD20+, PS über 50OriginAbramson Cancer Center, University of Pennsylvania, Philadelphia, JULIET trialAbteilung für Hämatologie, Universität Duisburg-Essen, DeutschlandASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milan, Italy, MOLTO trialAVOID Neutropenia, Merckle GmbHBattista Hospital and University, Turin, IELSG-10BC Cancer and The University of British Columbia, Vancouver, BC, CanadaCancer Center, Massachusetts General Hospital, BostonCancer Research UK Centre, University of Southampton, UK, SABRINA StudieC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, British Columbia, CanadaCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, ViPORCentre Antoine Lacassagne, Nice, France, LYSA groupCentre Henri-Becquerel, Rouen Cedex, France, POLARIX trialCity of Hope National Medical Center, Duarte, CADepartment of Clinical Hematology, Henri Mondor Hospital, Créteil, FrankreichDepartment of Haematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University MainzDepartment of Haematology, St George's Hospital, University of London, EnglandDepartment of Hematology, Saitama Cancer Center, Saitama, JapanDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USADepartment of Medicine, Mayo Clinic Rochester, Rochester, MinnesotaDepartment of Medicine, Stanford University School of Medicine, CADepartment of Oncology and Hematology, Hôpital de Hautepierre, Strasbourg, France, PIX203 trialDepartments of Leukemia and Experimental Therapeutics, The University of Texas, Anderson Cancer Center Departments of Leukemia and Experimental Therapeutics, The University of Texas, Anderson Cancer Center HoustonDivision of Hematology Oncology, University of California; Memorial Sloan-Kettering Cancer Center, New YorkDSHNHL 2002-1DSHNHL 2009-1, OPTIMAL > 60Euro18-trial Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena Cancer Center, ItalyGEL/TAMO cooperative groupe, SpanienGerman High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL), RICOVER-60Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigatorsGroupe d'Etude des Lymphomes de l'Adulte (GELA) investigators LNH03-2BGuys and St Thomas Hospital, London, United KingdomHematology, Universita Cattolica Sacro Cuore Campobasso, Campobasso, ItalyHopital Saint-Louis, Hemato-oncologie, Universite de Paris, Paris, FranceHopital Saint-Louis, Paris, FranceHopital Saint Louis, Paris, Frankreich, CORAL StudieHospices Civils de Lyon, Université Claude Bernard, FrankreichIcahn School of Medicine at Mount Sinai, New York, NY, EPCORE NHL-2 trialInstitut Universitaire du Cancer, Toulouse-Oncopole, Toulouse, FranceInternal Medicine I Saarland University Medical School, DSHNHL 2015-1Klinik für Onkologie und Hämatologie, Krankenhaus Nordwest, Frankfurt am Main, DeutschlandMassachusetts General Hospital Cancer Center, Boston, MA, USA, STARGLO trialMedical College of Wisconsin, Milwaukee, USAMedizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg, Germany, L-MIND studyNantes Medical University, Nantes, FranceNational Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaPeter MacCallum Cancer Centre, Melbourne, AustraliaPeter MacCallum Cancer Centre, Melbourne, Australia, COALITION StudyPrincess Margaret Cancer Centre, Ontario, CanadaRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA, ELM-1 trialSection of Lymphoma, M.D. Anderson Cancer Center, Houston, TXUniversity Hospital, Udine, ItalyUniversity of Liverpool, Liverpool, UK, SADAL trialUniversity of Southampton, Southampton, United Kingdom, REMoDL-B StudyUniversity of Texas M.D. Anderson Cancer Center, HoustonUniversity of Texas M.D. Anderson Cancer Center, Houston, USAUniversity of Washington/Fred Hutchinson Cancer Research Center, Seattle, WAUniversitätsklinikum des Saarlandes, Homburg, SMARTE-R-CHOP-14 Trial, DSHNHLWashington University School of Medicine, Siteman Cancer Center, St Louis, ECHELON-3 trialProtocols in Revision 132 protocols foundAtezolizumab 1200 / Venetoclax 400, Chronic Lymphocytic Leukemia, Richter Transformation, Cycle 9-18 (PID2781 V1.0)Bendamustine 90, diffuse large B-non-Hodgkin Lymphoma, Lymphodepletion (PID1830 V1.0)Brentuximab Vedotin 1.2 / Rituximab 1400 / Lenalidomide 20, diffuse large B-Non-Hodgkin Lymphoma, cycle 2+ (PID2913 V1.0)Brentuximab Vedotin 1.2 / Rituximab 375 / Lenalidomide 20, diffuse large B-Non-Hodgkin Lymphoma (PID2906 V1.0)DHAC - Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, Non-Hodgkin Lymphoma / Hodgkin Lymphoma. (PID2346 V1.0)DHAOx - Oxaliplatin 130 / Cytarabine 2000 / Dexamethasone 40, diffuse large B-Non-Hodgkin Lymphoma, cycle 3-6 (PID3119 V1.0)Epcoritamab (0.16/0.8/3/48) / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 1 (PID2927 V1.0)Epcoritamab (0.16/0.8/48), diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID2486 V1.1)Epcoritamab 48 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 2-3 (PID2928 V1.0)Epcoritamab 48 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 4 (PID2929 V1.0)Epcoritamab 48, diffuse large B-non-Hodgkin Lymphoma, cycle 10+ (PID2489 V1.2)Epcoritamab 48, diffuse large B-non-Hodgkin Lymphoma, Cycle 2-3 (PID2487 V1.2)Epcoritamab 48, diffuse large B-non-Hodgkin Lymphoma, cycle 4-9 (PID2488 V1.2)Epcoritamab 48, diffuse large B-Non-Hodgkin Lymphoma, cycle 5-9 (PID2930 V1.0)ESHAP - Etoposide 40 / Cisplatin 25 / Cytarabine 2000 / Methylprednisolone 375, Non-Hodgkin Lymphoma. (PID2348 V1.0)Fludarabine 25 / Cyclophosphamide 250, diffuse large B-non-Hodgkin Lymphoma, Lymphodepletion (PID1829 V1.0)Fludarabine 30 / Cyclophosphamide 300, B-non-Hodgkin Lymphoma, Lymphodepletion (PID2471 V2.0)Glofitamab 30 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 2-8 (PID2809 V1.1)Glofitamab 30, diffuse large B-non-Hodgkin Lymphoma, cycle 2-12 (PID2394 V1.1)Glofitamab 30, diffuse large B-Non-Hodgkin Lymphoma, cycle 7-8 (PID3134 V1.0)Glofitamab 30, diffuse large B-Non-Hodgkin Lymphoma, cycle 9-12 (PID2810 V1.1)Lenalidomide 25, diffuse large B-Non-Hodgkin Lymphoma, maintenance (PID2504 V1.0)Loncastuximab Tesirin 150, diffuse large B-non-Hodgkin Lymphoma, cycle 1-2 (PID2229 V1.0)Loncastuximab Tesirin 75, diffuse large B-non-Hodgkin Lymphoma, cycle 3+ (PID2230 V1.0)Methotrexate 500/3000, CNS Prophylaxis, Malignant Meningitis (PID1001 V1.1)MINE (Ifosfamide 1.33 / Mitoxantrone 8 / Etoposide 65), B-non-Hodgkin Lymphoma. (PID2389 V1.0)Mosunetuzumab (1/2/60), B-Non-Hodgkin Lymphoma, cycle 1 (PID2105 V1.0)Mosunetuzumab 30, B-Non-Hodgkin Lymphoma, cycle 3+ (PID2107 V1.1)Mosunetuzumab 30, diffuse large B-Non-Hodgkin Lymphoma, cycle 7-17 (PID2815 V1.0)Mosunetuzumab 60, B-Non-Hodgkin lymphoma, cycle 2 (PID2106 V1.1)Obinutuzumab (100/900/1000) / Atezolizumab 1200 / Venetoclax 20, Chronic Lymphocytic Leukemia, Richter Transformation, Cycle 1 (PID2778 V1.0)Obinutuzumab 1000 / Atezolizumab 1200 / Venetoclax (50/100/200), Chronic Lymphocytic Leukemia, Richter Transformation, Cycle 2 (PID2779 V1.0)Obinutuzumab 1000 / Atezolizumab 1200 / Venetoclax 400, Chronic Lymphocytic Leukemia, Richter Transformation, Cycle 3-8 (PID2780 V1.0)Obinutuzumab 1000 / Gemcitabine 1000 / Oxaliplatin 100 / Glofitamab (2.5/10), diffuse large B-Non-Hodgkin Lymphoma, cycle 1 (PID2808 V1.0)Obinutuzumab 1000 / glofitamab (2.5/10), diffuse large B-non-Hodgkin Lymphoma, cycle 1 (PID2393 V1.0)Odronextamab (0.2/0.5/2/10), diffuse large cell non-Hodgkin Lymphoma, cycle 1 (PID2886 V1.0)Odronextamab 160, diffuse large cell non-Hodgkin Lymphoma, cycle 2 (PID2893 V1.0)Odronextamab 160, diffuse large cell non-Hodgkin Lymphoma, cycle 3-4 (PID2894 V1.0)Odronextamab 320, diffuse large cell non-Hodgkin Lymphoma, maintenance 4 weeks (PID2896 V1.0)Odronextamab 320, diffuse large cell non-Hodgkin Lymphoma, cycle 2 weeks (PID2895 V1.0)Oxaliplatin 25 / Fludarabine 30 / Cytarabine 1000 / Rituximab 375, Chronic Lymphocytic Leukemia, Richter Transformation, Cycle 2+ (PID829 V1.1)Oxaliplatin 25 / Fludarabine 30 / Cytarabine 1000 / Rituximab 375, Chronic Lymphocytic Leukemia, Richter Transformation, Cycle 1 (PID828 V1.1)Pixantron 50, diffuse large B-non-Hodgkin Lymphoma (PID360 V1.1)Pola-R-CHP - Polatuzumab Vedotin 1.8 / Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100 / Glofitamab (2.5/10), diffuse large B-Non-Hodgkin Lymphoma, cycle 2 (PID3135 V1.0)Pola-R-CHP - Polatuzumab Vedotin 1.8 / Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100 / Glofitamab 30, diffuse large B-Non-Hodgkin Lymphoma, cycle 3-6 (PID3136 V1.0)Pola-R-CHP - Polatuzumab Vedotin 1.8 / Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 1-6 (PID1920 V1.0)Pola-R-CHP - Rituximab 375, Diffuse Large B-Non-Hodgkin Lymphoma, cycle 7-8. (PID1921 V1.0)Pola-R-miniCHP - Polatuzumab Vedotin 1.8 / Rituximab 375 / Cyclophosphamide 400 / Doxorubicin 25 / Prednisolone 40, diffuse large B-Non-Hodgkin Lymphoma (PID2680 V1.0)Polatuzumab Vedotin 1.8 / Mosunetuzumab (1/2/60), diffuse large B-Non-Hodgkin Lymphoma, cycle 1 (PID2812 V1.0)Polatuzumab Vedotin 1.8 / Mosunetuzumab 30, diffuse large B-Non-Hodgkin Lymphoma, cycle 3-6 (PID2814 V1.0)Polatuzumab Vedotin 1.8 / Mosunetuzumab 60, diffuse large B-Non-Hodgkin Lymphoma, cycle 2 (PID2813 V1.0)R- Benda - Rituximab 375 / Bendamustine 120, diffuse large B-non-Hodgkin Lymphoma (PID338 V1.1)R- Benda - Rituximab 375 / Bendamustine 90, diffuse large B-non-Hodgkin Lymphoma (PID1159 V1.0)R- ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID348 V1.1)R- ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, diffuse large B-non-Hodgkin Lymphoma, cycle 2+3 (PID349 V1.2)R-ACVBP - Cytarabine 100 consolidation, diffuse large B-non-Hodgkin Lymphoma Part D (PID343 V1.0)R-ACVBP - high-dose Methotrexate 3000, diffuse large B-non-Hodgkin Lymphoma, consolidation, part B (PID341 V1.2)R-ACVBP - Rituximab 375 / Doxorubicin 75 / Cyclophosphamide 1200 / Vindesin 2 / Bleomycin 10 / Prednisolone 60, induction, diffuse large B-non-Hodgkin Lymphoma Part A (PID340 V1.0)R-ACVBP - Rituximab 375 / Ifosfamide 1.5 / Etoposide 300 consolidation, diffuse large B-non-Hodgkin Lymphoma Part C (PID342 V1.0)R-ASHAP - Rituximab 375 / Doxorubicin 10 / Cisplatin 25 / Cytarabine 2000 / Methylprednisolone 375, diffuse large B-non-Hodgkin Lymphoma (PID359 V1.3)R-CEPP - Rituximab 375 / Cyclophosphamide 600 / Etoposide 70 / Procarbazine 60 / Prednisolone 60, diffuse large B-Non-Hodgkin Lymphoma (PID2508 V1.0)R-CHOEP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Etoposide 100 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID722 V1.0)R-CHOP (Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100) / Bortezomib 1.6, diffuse large B-Non-Hodgkin Lymphoma, cycle 2-6 (PID2682 V1.0)R-CHOP (Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 60) Decitabine 10, diffuse large B-Non-Hodgkin Lymphoma (PID2759 V1.0)R-CHOP - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100 / Glofitamab (2.5/10), diffuse large B-Non-Hodgkin Lymphoma, cycle 2 (PID3132 V1.0)R-CHOP - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100 / Glofitamab 30, diffuse large B-Non-Hodgkin Lymphoma, cycle 3-6 (PID3133 V1.0)R-CHOP - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 1 (PID2681 V1.0)R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 1-6 (PID112 V1.1)R-CHOP 14 - Rituximab 375, diffuse large B-non-Hodgkin Lymphoma, cycle 7-8 (PID1448 V1.0)R-CHOP 21 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100 / Methotrexate 12, Testicular Lymphoma, Cycle 1 (PID901 V1.1)R-CHOP 21 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100 / Methotrexate 12, Testicular Lymphoma, Cycle 2 (PID902 V1.1)R-CHOP 21 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, Testicular Lymphoma, Cycle 3-6 (PID903 V1.0)R-CHOP 21 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 40, diffuse large B-non-Hodgkin Lymphoma (PID113 V1.2)R-COEP - Rituximab 375 / Cyclophosphamide 750 / Etoposide (50/100) / Vincristine 2 / Prednisolone 45, diffuse large B-non-Hodgkin Lymphoma (PID1777 V1.0)R-COMP 21 - Rituximab 375 / Cyclophosphamide 750 / Vincristine 2 / lip. doxorubicin 50 / Prednisolone 100, diffuse large B-cell lymphoma (PID125 V1.0)R-CPOP 21 - Rituximab 375 / Cyclophosphamide 750 / Pixantron 88 / Vincristine 2 / Prednisolone 40, diffuse large B-non-Hodgkin Lymphoma (PID931 V1.0)R-DexaBEAM - Rituximab 375 / Dexamethasone 8 / Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 20, B-Non-Hodgkin Lymphoma (PID1006 V1.0)R-DHAC - Rituximab 375 / Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, B-Non-Hodgkin's Lymphoma/Hodgkin's Lymphoma (PID2345 V1.0)R-DHAOx - Rituximab 375 / Oxaliplatin 130 / Cytarabine 2000 / Dexamethasone 40, diffuse large B-Non-Hodgkin Lymphoma, cycle 1 (PID3115 V1.0)R-DHAOx - Rituximab 375 / Oxaliplatin 130 / Cytarabine 2000 / Dexamethasone 40, diffuse large B-Non-Hodgkin Lymphoma, cycle 2 (PID3118 V1.0)R-DHAP - Rituximab 375 / Cisplatin 100 / Cytarabine 2000 / Dexamethasone 40, diffuse large B-non-Hodgkin Lymphoma (PID350 V1.2)R-ESHAP - Rituximab 375 / Etoposide 40 / Cisplatin 25 / Cytarabine 2000 / Methylprednisolone 250, diffuse large B-non-Hodgkin Lymphoma (PID358 V1.1)R-GCVP - Rituximab 375 / Gemcitabine 750 / Cyclophosphamide 750 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID1774 V1.1)R-GDC - Rituximab 375 / Gemcitabine 1000 / Dexamethasone 40 / Carboplatin 5, diffuse large B-non-Hodgkin Lymphoma (PID1681 V1.0)R-GDP - Rituximab 375 / Gemcitabine 1000 / Dexamethasone 40 / Cisplatin 75, diffuse large B-non-Hodgkin Lymphoma (PID605 V1.4)R-miniCHOP - Rituximab 1400 / Cyclophosphamide 400 / Doxorubicin 25 / Vincristine 1 / Prednisolone 40, diffuse large B-Non-Hodgkin Lymphoma, cycle 2-6, variant 1 (PID2536 V1.0)R-miniCHOP - Rituximab 375 / Cyclophosphamide 400 / Doxorubicin 25 / Vincristine 1 / Prednisolone 40, diffuse large B-non-Hodgkin Lymphoma (PID339 V1.2)R-miniCHOP - Rituximab 375 / Cyclophosphamide 400 / Doxorubicin 25 / Vincristine 1 / Prednisolone 40, diffuse large B-Non-Hodgkin Lymphoma, cycle 1, variant 1 (PID2535 V1.0)Rituximab 1400, single dose subcutaneous (PID310 V2.0)Rituximab 25, Malignant Meningitis (PID2571 V1.0)Rituximab 375 / Bendamustine 120 / Carboplatin 5 / Etoposide 100, B-Non-Hodgkin Lymphoma. (PID2390 V1.0)Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, B-non-Hodgkin Lymphoma (PID354 V1.0)Rituximab 375 / Doxorubicin Liposomal 30 / Cyclophosphamide 750 / Vincristine 2 / Prednisolone 40, diffuse large B-Non-Hodgkin Lymphoma, cycle 1 (PID2502 V1.0)Rituximab 375 / Doxorubicin Liposomal 30 / Cyclophosphamide 750 / Vincristine 2 / Prednisolone 40, diffuse large B-Non-Hodgkin Lymphoma, cycle 2-6 (PID2503 V1.0)Rituximab 375 / Polatuzumab Vedotin 1.8 / Bendamustine 90, diffuse large B-non-Hodgkin Lymphoma, cycle 2-6 (PID1423 V1.1)Rituximab 375 / Polatuzumab Vedotin 1.8 / Bendamustine 90, diffuse large B-non-Hodgkin Lymphoma, cycle 1 (PID1422 V1.1)Selinexor 60, diffuse large B-non-Hodgkin Lymphoma (PID1796 V1.0)SMARTE- R-CHOP 14 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 2,4,6 (PID929 V1.0)SMARTE- R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID926 V1.0)SMARTE- R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 3.5 (PID930 V1.0)SMARTE- R-CHOP 14 - Rituximab 375, diffuse large B-non-Hodgkin Lymphoma, cycle 7+ (PID75 V1.0)Study - Level - Gemcitabine 1000 / Oxaliplatin 100, Aggressive Non-Hodgkin Lymphoma (PID972 V1.0)Study - Level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, Cycle 1 (PID968 V1.2)Study - level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 2+ (PID970 V1.2)Study - Level - Nivolumab 240 / Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, Cycle 1 (PID967 V1.2)Study - level - Nivolumab 240 / Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 2+ (PID969 V1.2)Study - Level - Nivolumab 240, diffuse large B-Non-Hodgkin Lymphoma, consolidation (PID971 V1.1)Study - Level - Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID973 V1.0)Study - Level - Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 2+ (PID974 V1.0)Study - OPTIMAL - Arm F-A, R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID1124 V1.0)Study - OPTIMAL - Arm F-B, R-CHLIP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine Liposomal 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID1123 V1.0)Study - OPTIMAL - Arm LF-A, R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID1121 V1.0)Study - OPTIMAL - Arm LF-B, R-CHLIP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine Liposomal 1.67 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID1122 V1.0)Study - OPTIMAL - Arm LF-C optimised, CHOP 14 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 6 (PID1131 V1.0)Study - OPTIMAL - Arm LF-C optimised, R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID1126 V1.0)Study - OPTIMAL - Arm LF-C optimised, R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 2-5 (PID1127 V1.0)Study - OPTIMAL - Arm LF-D optimised, CHLIP 14 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine liposomal 1.67 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 6 (PID1130 V1.0)Study - OPTIMAL - Arm LF-D optimised, R-CHLIP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine Liposomal 1.67 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID1125 V1.0)Study - OPTIMAL - Arm LF-D optimised, R-CHLIP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine Liposomal 1.67 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 2-5 (PID1128 V1.0)Study - OPTIMAL - Rituximab 375 / high dose Methotrexate 3000, diffuse large B-non-Hodgkin Lymphoma, CNS Prophylaxis (PID1133 V1.0)Study - OPTIMAL - Pre-phase, Diffuse Large B-Non-Hodgkin Lymphoma (PID1120 V1.0)Avoid study - R-CHOP 21 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID706 V1.0)Study-OPTIMAL - Rituximab 375, DLBCL (PID1132 V1.0)Tafasitamab 12 / Lenalidomide 25 - Tafasitamab 12, maintenance, diffuse large B-non-Hodgkin Lymphoma, cycle 13+ (PID1851 V1.0)Tafasitamab 12 / Lenalidomide 25, diffuse large B-non-Hodgkin Lymphoma, cycle 1 (PID1848 V1.0)Tafasitamab 12 / Lenalidomide 25, diffuse large B-non-Hodgkin Lymphoma, cycle 2-3 (PID1849 V1.1)Tafasitamab 12 / Lenalidomide 25, diffuse large B-non-Hodgkin Lymphoma, cycle 4-12 (PID1850 V1.0)Venetoclax 400, Chronic Lymphocytic Leukemia, Richter Transformation, Cycle 19-35 (PID2782 V1.0)Vincristine 1 / Prednisolone 100, Pre-phase, diffuse large B-non-Hodgkin Lymphoma (PID69 V1.1)Vincristine 1 / Prednisolone 60, diffuse large B-non-Hodgkin Lymphoma (PID1778 V1.0)ViPOR - Obinutuzumab 1000 / Prednisolone 100 / Ibrutinib 560 / Lenalidomide 15 / Venetoclax (50/200/600/800), diffuse large B-non-Hodgkin lymphoma, cycle 1 (PID2666 V1.0)ViPOR - Obinutuzumab 1000 / Prednisolone 100 / Ibrutinib 560 / Lenalidomide 15 / Venetoclax 800, diffuse large B-cell non-Hodgkin Lymphoma, cycle 2-6 (PID2677 V1.0)
